title: Anti-inflammatory and anti-atherogenic effects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice.
abstract: A strong negative correlation between polyphenols consumption and coronary heart disease has been extensively documented. These results prompted investigations on the mechanisms responsible for polyphenols effects in cardiovascular disease. The aim of this work was to investigate in apoE KO mice the effect of P183/1 (a mixture of cathechin, caffeic acid and resveratrol) on atherosclerosis and gene expression patterns in the vascular wall. ApoE KO mice were fed a diet supplemented with P183/1, 40 and 160 mg/kg body weight/day for 8 weeks. The supplementation with the high dose of P183/1 significantly reduced the presence of atherosclerotic plaque by 40 and 36% in the aortic sinus and in the ascending aorta, respectively. This reduction was associated with a reduced expression of markers for macrophages, lymphocytes (both Th1 and Th2) and of MCP-1, MIP-1alpha, MIP-1beta, CCR1, CCR2 and ET1 in the vascular wall. In conclusion, P183/1 supplementation significantly decreases atherosclerosis in ApoE KO mice by affecting inflammatory cells recruitment and expression of pro-inflammatory chemokines in the vascular wall.
authors.affiliation: Department of Pharmacological Sciences, University of Milan, Via Balzaretti 9, 20133 Milan, Italy.
authors.forename: Giuseppe Danilo
authors.initials: GD
authors.lastname: Norata
authors.forename: Patrizia
authors.initials: P
authors.lastname: Marchesi
authors.forename: Silvia
authors.initials: S
authors.lastname: Passamonti
authors.forename: Angela
authors.initials: A
authors.lastname: Pirillo
authors.forename: Francesco
authors.initials: F
authors.lastname: Violi
authors.forename: Alberico Luigi
authors.initials: AL
authors.lastname: Catapano
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001011:Aorta / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D001057:Apolipoproteins E / Q000172:deficiency* / Q000235:genetics; D050197:Atherosclerosis / Q000209:etiology / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D002109:Caffeic Acids / Q000494:pharmacology*; D002317:Cardiovascular Agents / Q000494:pharmacology*; D002392:Catechin / Q000494:pharmacology*; D016207:Cytokines / Q000235:genetics / Q000378:metabolism; D004041:Dietary Fats; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D019332:Endothelin-1 / Q000235:genetics / Q000378:metabolism; D015870:Gene Expression / Q000187:drug effects*; D051379:Mice; D018345:Mice, Knockout; D012333:RNA, Messenger / Q000378:metabolism; D019707:Receptors, Chemokine / Q000235:genetics / Q000378:metabolism; D013267:Stilbenes / Q000494:pharmacology*
chemical_list: D000893:Anti-Inflammatory Agents; D001057:Apolipoproteins E; D002109:Caffeic Acids; D002317:Cardiovascular Agents; D016207:Cytokines; D004041:Dietary Fats; D019332:Endothelin-1; C520670:P183-1; D012333:RNA, Messenger; D019707:Receptors, Chemokine; D013267:Stilbenes; D002392:Catechin